About e-Therapeutics (LON:ETX)
e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology and chemical biology. It focuses on the discovery of drugs for cancer. The company's drug candidates include ETS2101, which is in Phase Ib clinical trial for the treatment of hepatocellular and pancreatic cancer. It also develops ETS6103; and ETX1153c products. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-40.76%
Return on Assets-37.10%
e-Therapeutics (LON:ETX) Frequently Asked Questions
What is e-Therapeutics' stock symbol?
e-Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX."
How were e-Therapeutics' earnings last quarter?
e-Therapeutics plc (LON:ETX) issued its earnings results on Tuesday, March, 27th. The company reported ($2.00) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($2.10) by $0.10. View e-Therapeutics' Earnings History.
Who are some of e-Therapeutics' key competitors?
Some companies that are related to e-Therapeutics include InMed Pharmaceuticals (IMLFF), Navidea Biopharmaceuticals (NAVB), Botanix Pharmaceuticals (BOT), IntelGenx Technologies (IGX), BELLUS Health (BLU), Medicenna Therapeutics (MDNA), Destiny Pharma (DEST), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), OptiBiotix Health (OPTI), Scancell (SCLP), Synthetic Biologics (SYN), DiaMedica Therapeutics (DMA) and Antibe Therapeutics (ATE).
Who are e-Therapeutics' key executives?
e-Therapeutics' management team includes the folowing people:
- Mr. Steven Medlicott, CFO, Fin. Director & Exec. Director (Age 53)
- Dr. Raymond Barlow B.Sc. (Hons), Ph.D., MBA, CEO & Director (Age 49)
- Mrs. Susan M. Steven, Company Sec. (Age 55)
Has e-Therapeutics been receiving favorable news coverage?
News coverage about ETX stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. e-Therapeutics earned a news sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the company an impact score of 47.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of e-Therapeutics?
Shares of ETX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is e-Therapeutics' stock price today?
One share of ETX stock can currently be purchased for approximately GBX 7.38.
How big of a company is e-Therapeutics?
e-Therapeutics has a market capitalization of £16.61 million.
How can I contact e-Therapeutics?
e-Therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000.
MarketBeat Community Rating for e-Therapeutics (ETX)MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics and other stocks. Vote "Outperform" if you believe ETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETX will underperform the S&P 500 over the long term. You may vote once every thirty days.